| Product Name | Dovitinib - API |
| Product Code | DA-D271-01 |
| Chemical name | Dovitinib |
| Synonyms | GFKI 258; TK-258; TKI 258; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one; 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-; |
| Impurity | NA |
| CAS Number | 405169-16-6 |
| Alternate CAS # | NA |
| Molecular form | C21H21FN6O |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 392.44 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,fine chemicals |
| Boiling Point | NA |
| Applications | Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
